View More Recent Stories

Mar 17, 2025 07:06AM Cantor Fitzgerald says 15% of biotech companies down 40% or more
Mar 13, 2025 06:46AM Cantor Fitzgerald Reiterates Overweight Rating on Bicara Therapeutics Inc (BCAX)
Feb 11, 2025 04:02PM Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01
Jan 27, 2025 09:33AM Stifel Reiterates Buy Rating on Bicara Therapeutics Inc (BCAX)
Jan 27, 2025 08:18AM Bicara Therapeutics (BCAX) Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
Jan 27, 2025 08:01AM Bicara Therapeutics (BCAX) Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa
Jan 27, 2025 07:13AM Bicara Therapeutics Inc (BCAX) PT Raised to $45 at H.C. Wainwright
Nov 5, 2024 06:39AM Rodman and Renshaw Starts Bicara Therapeutics Inc (BCAX) at Buy
Oct 8, 2024 06:36AM Cantor Fitzgerald Starts Bicara Therapeutics Inc (BCAX) at Overweight
Oct 8, 2024 05:29AM TD Cowen Starts Bicara Therapeutics Inc (BCAX) at Buy
Oct 8, 2024 03:39AM Morgan Stanley Starts Bicara Therapeutics Inc (BCAX) at Overweight
Oct 8, 2024 02:30AM Stifel Starts Bicara Therapeutics Inc (BCAX) at Buy
Sep 13, 2024 01:11PM Bicara Therapeutics (BCAX) Opens at $26.25 , Upsized IPO Priced at $18
Sep 6, 2024 06:39AM Bicara Therapeutics (BCAX) Files for 11.765M Share IPO at $16-$18/sh
Sep 3, 2024 07:29AM Bicara Therapeutics (BCAX) Files for Proposed IPO
View More Recent Stories